We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.34B
AUM Growth
+$159M
Cap. Flow
+$143M
Cap. Flow %
6.11%
Top 10 Hldgs %
72.34%
Holding
34
New
6
Increased
14
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$55M
2
SRRK icon
Scholar Rock
SRRK
+$50.2M
3
MRUS
Merus
MRUS
+$42.9M
4
ALKS icon
Alkermes
ALKS
+$40.9M
5
BBIO icon
BridgeBio Pharma
BBIO
+$35.1M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$78M
2
ARGX icon
argenx
ARGX
+$35.3M
3
CYTK icon
Cytokinetics
CYTK
+$34.5M
4
INSM icon
Insmed
INSM
+$34.4M
5
MTSR
Metsera Inc
MTSR
+$32.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
26
Immatics
IMTX
$1.18B
$16.9M 0.72%
3,144,157
+1,237,049
+65% +$6.14M
ERAS icon
27
Erasca
ERAS
$6.3B
$15.1M 0.65%
11,907,182
+1,104,828
+10% +$1.48M
CBIO
28
Crescent Biopharma
CBIO
$537M
$10.4M 0.44%
+642,721
New +$13.6M
ARGX icon
29
argenx
ARGX
$53.4B
– –
-59,679
Closed -$35.3M
ARQT icon
30
Arcutis Biotherapeutics
ARQT
$3.36B
– –
-1,465,334
Closed -$22.9M
CYTK icon
31
Cytokinetics
CYTK
$10.5B
– –
-858,664
Closed -$34.5M
EWTX icon
32
CALL
Edgewise Therapeutics
EWTX
$4.13B
– –
-500,000
Closed -$11M
INSM icon
33
Insmed
INSM
$21.4B
– –
-451,359
Closed -$34.4M
MTSR
34
DELISTED
Metsera Inc
MTSR
– –
-1,191,462
Closed -$32.4M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Paradigm Biocapital Advisors held 34 positions worth $2.34B, up 7.3% from $2.18B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Paradigm Biocapital Advisors deployed $143M of net new capital in Q2 2025, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was Scholar Rock: 1,600,554 shares worth $56.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $78M trimmed.

  • Paradigm Biocapital Advisors's largest Q2 2025 buy was Scholar Rock: 1,600,554 shares worth $56.7M.
  • Paradigm Biocapital Advisors added most to Vaxcyte in Q2 2025, an estimated $55M increase.
  • Paradigm Biocapital Advisors's biggest Q2 2025 reduction was BeOne Medicines Ltd, cutting an estimated $78M.
  • Paradigm Biocapital Advisors fully exited argenx in Q2 2025, selling an estimated $35.3M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 72% of its $2.34B portfolio in Q2 2025.
  • Paradigm Biocapital Advisors opened 6 new positions and closed 6 in Q2 2025.
  • Paradigm Biocapital Advisors's portfolio value rose 7.3% quarter-over-quarter to $2.34B.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.